ISSN: 1859 - 2872
The initial results of treatment umbilical cord derived mesenchymal stem cells in chronic obstructive pulmonary disease patients
Main Article Content
Keywords
Abstract
Objective: To evaluate the changes of clinical and paraclinical characteristics in chronic obstructive pulmonary disease patients after treatment umbilical cord derived mesenchymal stem cell. Subject and method: 15 stable COPD patients were enrolled with C and D groups in accordance with GOLD 2018. Patients were infused intravenously allogeneic umbilical cord derived mesenchymal stem cell with dosage of 1.5 x 106 MSCs per kilogram of weight every 6 months for 12 months. Patients were followed every 3 months for 12 months: Clinical symptoms, quality-of-life (CAT), mMRC, and 6 minute walking test (6MWT), number of exacerbations, CRP, lung function test and arterial blood gas. Result: There was a significantly reduced mMRC score, CAT indexes, number of exacerbation and improve 6MWT values. However, the forced expiratory volume in 1 second, but CRP levels were no significantly reduced after treatment (6 and 12 months) compared with those before the treatment. Conclusion: Allogeneic MSCs administration has initially improved symptoms, quality of life, exercise tolerance and reduced exacerbations in COPD patients with C and D groups.
Article Details
References
2. Gao F, Chiu SM, Motan DAL et al (2016) Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell death & disease 7(1): 2062-2062.
3. Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood105(4): 1815-1822.
4. Humbert M, Guignabert C, Bonnet S et al (2019) Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives. The European respiratory journal 53(1): 1801-1887.
5. Barberà JA, Isabel Blanco Vich M (2019) New insights into the pathobiology of pulmonary hypertension in COPD. Medscape.
6. Zakrzewski W, Dobrzyński M, Szymonowicz M et al (2019) Stem cells: Past, present, and future. Stem cell research & therapy 10(1): 68-68.
7. Shenghui H, Makada D, Morrison SJ (2009) Mechanisms of stem cell self-renewal. Annual Review of Cell and Developmental Biology 25(1): 377-406.
8. Singh VK, Saini A, Kalsan M et al (2016) Describing the stem cell potency: The various methods of functional assessment and in silico diagnostics. Frontiers in cell and developmental biology 4: 134-134.
9. Kokturk N, Yıldırım F, Gülhan PY et al (2018) Stem cell therapy in chronic obstructive pulmonary disease. How far is it to the clinic? American journal of stem cells 7(3): 56-71.
10. Ankrum JA, Ong JF, Karp JM (2014) Mesenchymal stem cells: Immune evasive, not immune privileged. Nature biotechnology 32(3): 252-260.
11. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2018, Global initiative for Chronic obstructive lung disease.
12. Weiss DJ, Casaburi R, Flannery R et al (2013) A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 143(6): 1590-1598.
13. Nguyễn Huy Lực (2002) Đặc điểm lâm sàng, thông khí phổi, khí máu động mạch theo thể và giai đoạn của bệnh phổi tắc nghẽn mạn tính và hen phế quản. Tạp chí Y học thực hành, số 4.
14. Stolk J, Broekman W, Mauad T et al (2016) A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema. QJM 109(5): 331-336.
15. Ribeiro-Paes JT, Bilaqui A, Greco OT et al (2001) Unicentric study of cell therapy in chronic obstructiva pulmonary disease/Pulmonary emphysema. International Journal of COPD, International Journal of COPD 6: 63-71.
Article Sidebar
